FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387361657> ?p ?o ?g. }

• W4387361657 abstract "Abstract Disclosure: H. Deshmukh: None. E. Ssemmondo: None. K. Adeleke: None. L. Batten: None. M. Aye: None. T. Sathyapalan: None. Introduction: There are limited data on the effect of time to remission of acromegaly and survival in people living with acromegaly Methods: The UK Acromegaly Register collected routine biochemical and clinical data on patients with acromegaly. We defined remission of acromegaly as Growth hormone (GH) controlled at ≤2 μg/l following the diagnosis of acromegaly. Time to first remission was defined as the difference between the date of diagnosis and the first GH date ≤2 μg/l in the longitudinal follow-up data (following surgery and/or medical therapy). We used a t-test to compare the mean survival and used the cox-proportional hazard model to assess the effect of time to remission on survival in acromegaly. Results: The study consisted of 3750 participants in the UK acromegaly register with complete data, of which 2472 (65%) participants achieved remission of acromegaly. The mean time to remission with somatostatin analogs (SA) and dopamine agonist (DA) therapy was 4.5 yrs and 7.3 years, respectively (P&lt;0.001). The mean survival was significantly higher in those who achieved remission of acromegaly as compared to those who did not (25.5 yrs vs 21.9yrs P&lt;0.001) achieve remission. In those who achieved remission, (median follow-up period of 23.9 years), there was 15% mortality in those who achieved remission within 1 year and 23% mortality in those who needed more than 1 year to achieve remission. In the cox-proportional hazard model adjusted for, baseline GH, age at diagnosis, and gender, a shorter time to regression of acromegaly was associated with improved survival (HR=0.92(0.91-0.93) P&lt;0.001). Conclusion: This large population-based study of acromegaly showed that a shorter time to remission is associated with improved survival. Presentation: Thursday, June 15, 2023" @default.
• W4387361657 created "2023-10-06" @default.
• W4387361657 creator A5037975480 @default.
• W4387361657 creator A5062170233 @default.
• W4387361657 creator A5065219120 @default.
• W4387361657 creator A5070087885 @default.
• W4387361657 creator A5088604122 @default.
• W4387361657 creator A5089457205 @default.
• W4387361657 date "2023-10-01" @default.
• W4387361657 modified "2023-10-06" @default.
• W4387361657 title "THU060 Time To First Remission, Medical Therapy And Survival In Acromegaly: UK Acromegaly Register (UKAR) Study" @default.
• W4387361657 doi "https://doi.org/10.1210/jendso/bvad114.1140" @default.
• W4387361657 hasPublicationYear "2023" @default.
• W4387361657 type Work @default.
• W4387361657 citedByCount "0" @default.
• W4387361657 crossrefType "journal-article" @default.
• W4387361657 hasAuthorship W4387361657A5037975480 @default.
• W4387361657 hasAuthorship W4387361657A5062170233 @default.
• W4387361657 hasAuthorship W4387361657A5065219120 @default.
• W4387361657 hasAuthorship W4387361657A5070087885 @default.
• W4387361657 hasAuthorship W4387361657A5088604122 @default.
• W4387361657 hasAuthorship W4387361657A5089457205 @default.
• W4387361657 hasBestOaLocation W43873616571 @default.
• W4387361657 hasConcept C126322002 @default.
• W4387361657 hasConcept C187212893 @default.
• W4387361657 hasConcept C207103383 @default.
• W4387361657 hasConcept C2776694085 @default.
• W4387361657 hasConcept C2777433750 @default.
• W4387361657 hasConcept C2984496839 @default.
• W4387361657 hasConcept C3018657049 @default.
• W4387361657 hasConcept C44249647 @default.
• W4387361657 hasConcept C71315377 @default.
• W4387361657 hasConcept C71924100 @default.
• W4387361657 hasConcept C90924648 @default.
• W4387361657 hasConceptScore W4387361657C126322002 @default.
• W4387361657 hasConceptScore W4387361657C187212893 @default.
• W4387361657 hasConceptScore W4387361657C207103383 @default.
• W4387361657 hasConceptScore W4387361657C2776694085 @default.
• W4387361657 hasConceptScore W4387361657C2777433750 @default.
• W4387361657 hasConceptScore W4387361657C2984496839 @default.
• W4387361657 hasConceptScore W4387361657C3018657049 @default.
• W4387361657 hasConceptScore W4387361657C44249647 @default.
• W4387361657 hasConceptScore W4387361657C71315377 @default.
• W4387361657 hasConceptScore W4387361657C71924100 @default.
• W4387361657 hasConceptScore W4387361657C90924648 @default.
• W4387361657 hasIssue "Supplement_1" @default.
• W4387361657 hasLocation W43873616571 @default.
• W4387361657 hasOpenAccess W4387361657 @default.
• W4387361657 hasPrimaryLocation W43873616571 @default.
• W4387361657 hasRelatedWork W173396347 @default.
• W4387361657 hasRelatedWork W2003682545 @default.
• W4387361657 hasRelatedWork W2055086560 @default.
• W4387361657 hasRelatedWork W2082468811 @default.
• W4387361657 hasRelatedWork W2094176660 @default.
• W4387361657 hasRelatedWork W2100779781 @default.
• W4387361657 hasRelatedWork W2475144847 @default.
• W4387361657 hasRelatedWork W2510751355 @default.
• W4387361657 hasRelatedWork W2944799263 @default.
• W4387361657 hasRelatedWork W4206014946 @default.
• W4387361657 hasVolume "7" @default.
• W4387361657 isParatext "false" @default.
• W4387361657 isRetracted "false" @default.
• W4387361657 workType "article" @default.